REGNREGNHealthcare · Biotechnology

REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Nov 2026
$904
+0.14% on the day

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $982 — +8.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 6 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$93.4B
Ticker Nerd rank
97/ 100
Median analyst target
$982
Analysts covering
28
Revenue$4.3B+16.7% y/y
Operating income$1.4B
Net income$1.3B
Free cash flow$521.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
+22.4%
YTD
+17.6%
1Y
+40.5%
From 52W high
−7.1%
From 52W low
+50.7%
$600
$973
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Nov 2026
97/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Value
96
Volatility
96
Momentum
91
Quality
83
Growth
79
Issuance
77
Accruals
37
Size
3

Revisions (96): Analysts have, on balance, been raising their forecasts.

Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

REGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$700$800$900$1,000$1,100$1,200Jan 26Apr 26Jul 26Oct 26REGNHigh $1,175Median $982Low $812

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
19 Buy9 Hold0 Sell
Low $812Median $982High $1,175

The green dot is the last close — the median target sits +8.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 17 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
2 Nov 2026B of A SecuritiesMaintainsBuy$908 → $1,030
2 Nov 2026BairdMaintainsNeutral$761 → $875
2 Nov 2026BernsteinMaintainsMarket Perform$756 → $812
2 Nov 2026Canaccord GenuityMaintainsBuy$922 → $1,175
2 Nov 2026Cantor FitzgeraldMaintainsOverweight$795 → $980
2 Nov 2026Evercore ISI GroupMaintainsOutperform$900 → $1,075
2 Nov 2026GuggenheimMaintainsBuy$1,030 → $1,100
2 Nov 2026Leerink PartnersMaintainsMarket Perform$835 → $997
2 Nov 2026Morgan StanleyMaintainsEqual-Weight$779 → $855
2 Nov 2026RBC CapitalMaintainsSector Perform$810 → $913
2 Nov 2026Truist SecuritiesMaintainsBuy$780 → $982
2 Nov 2026Wells FargoMaintainsEqual-Weight$750 → $925
31 Oct 2026JP MorganMaintainsOverweight—
30 Oct 2026CitigroupMaintainsNeutral$740 → $825
30 Oct 2026JP MorganMaintainsOverweight$950 → $1,050
28 Oct 2026Canaccord GenuityMaintainsBuy$875 → $922
21 Oct 2026TD CowenMaintainsBuy—
21 Oct 2026TD CowenMaintainsBuy$960 → $980
19 Oct 2026Piper SandlerMaintainsOverweight—
19 Oct 2026Piper SandlerMaintainsOverweight$854 → $865

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

REGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

REGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Nov 2026, Regeneron Pharmaceuticals, Inc. returned +40.5% against +10.9% for the S&P 500, dividends included.

REGN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26REGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+29.3%
Analysts raising
9
Analysts cutting
1
Fundamentals

Regeneron Pharmaceuticals, Inc. (REGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.0×

Cheaper than 37% of US stocks

Price / sales
5.5×

Cheaper than 21% of US stocks

Price / book
2.7×

Cheaper than 33% of US stocks

EV / EBITDA
14.9×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
36.3%

Higher than 81% of US stocks

Earnings growth (YoY)
33.5%

Higher than 68% of US stocks

Gross margin
86.6%

Higher than 95% of US stocks

Operating margin
40.5%

Higher than 92% of US stocks

Net margin
28.5%

Higher than 88% of US stocks

Returns & dividend
Return on equity
14.9%

Higher than 74% of US stocks

Return on assets
7.6%

Higher than 86% of US stocks

Dividend yield
0.4%

Higher than 65% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Regeneron Pharmaceuticals, Inc. (REGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regeneron Pharmaceuticals, Inc. has a market value of $93.4B and an enterprise value of $84.0B.

  • Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 36.3% year on year.

  • Net income over the same four quarters: $4.3B, a 27.9% net margin.

  • Diluted earnings per share, trailing twelve months: $40.46.

  • Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.

  • Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 103.1M.

  • Trailing P/E: 20.0×; forward P/E: 12.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.42%, paying out 8% of earnings.

  • Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Nov 2026

Data provided by Twelve Data

Peers

REGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REGNRegeneron Pharmaceuticals, Inc.$93.4B97
MRNAModerna, Inc.$101.5B85
VRTXVertex Pharmaceuticals, Inc.$138.8B62
RVMDRevolution Medicines, Inc.$40.1B58
RPRXRoyalty Pharma Plc$38.8B97
ROIVRoivant Sciences Ltd.$27.8B44
INSMInsmed, Inc.$25.0B74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REGN news & analysis

Why Regeneron (REGN) Might be Well Poised for a Surge

Zacks Investment Research · 4 Nov 2026positive

Zacks Investment Research says Regeneron shares have started gaining and may continue moving higher in the near term, citing solid earnings estimate revisions.

Why it matters — REGN watchers may track earnings estimate revisions as a factor cited in the report’s near-term view of the shares.

REGN vs. ILMN: Which Stock Is the Better Value Option?

Zacks Investment Research · 4 Nov 2026neutral

Zacks Investment Research posed a comparison of Regeneron and Illumina, asking which stock offers the better value opportunity. The excerpt does not provide the comparison’s findings.

Why it matters — REGN watchers may be interested in how the stock is evaluated against Illumina for value, though the excerpt gives no conclusion.

Regeneron Announces Investor Conference Presentations

GlobeNewsWire · 2 Nov 2026neutral

Regeneron announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London, with a webcast scheduled for 2:00 p.m.

Why it matters — REGN watchers can follow management’s conference participation through the webcast.

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Benzinga · 2 Nov 2026positive

Regeneron reported better-than-expected third-quarter 2026 results, with adjusted earnings of $20.07 per share, up 70% year over year and above the $16.19 analyst consensus estimate.

Why it matters — The earnings beat and year-over-year increase are key results for REGN watchers, and the headline says analysts raised their forecasts after the report.

FAQ

Frequently asked questions about REGN stock

What is the REGN stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $982, with estimates ranging from $812 to $1,175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REGN stock a buy right now?

Of the 28 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 across roughly 4,600 US stocks as at 6 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REGN?

As at 6 Nov 2026, Regeneron Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will REGN stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +8.6% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 as at 6 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REGN stock forecast for 2030?

No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $812 to $1,175 over the next 12 months.

How has REGN stock performed over the past year?

Regeneron Pharmaceuticals, Inc. returned +40.5% over the 12 months to 6 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases.

What is the latest news on REGN?

The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Why Regeneron (REGN) Might be Well Poised for a Surge". Zacks Investment Research says Regeneron shares have started gaining and may continue moving higher in the near term, citing solid earnings estimate revisions.

Company

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.

CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com